MacroGenics, Inc.
MGNX Real Time Price USDRecent trades of MGNX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in MGNX holdings by institutional investors
Quarterly net insider trading by MGNX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
MGNX Estimated quarterly lobbying spending
MGNX Revenue by Segment or Geography
New MGNX patent grants
-
Patent Title: Covalent diabodies and uses thereof May. 08, 2018
-
Patent Title: Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof Apr. 03, 2018
-
Patent Title: Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof Mar. 06, 2018
-
Patent Title: Antibodies reactive with b7-h3 and uses thereof Feb. 20, 2018
-
Patent Title: Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin Feb. 13, 2018
-
Patent Title: Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses thereof Nov. 21, 2017
-
Patent Title: Combination of fcγriib-specific antibodies and cd20-specific antibodies and methods of use thereof Aug. 22, 2017
-
Patent Title: Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof Jul. 25, 2017
-
Patent Title: Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof Jul. 25, 2017
-
Patent Title: Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for fcγr Jul. 18, 2017
-
Patent Title: Bcr-complex-specific antibodies and methods of using same Jul. 04, 2017
-
Patent Title: Cd3-binding molecules capable of binding to human and non-human cd3 Mar. 07, 2017
-
Patent Title: B7-h3l cell surface antigen and antibodies that bind thereto Feb. 21, 2017
-
Patent Title: Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express b7-h3 and uses thereof Nov. 08, 2016
-
Patent Title: Her2/neu-specific antibodies and methods of using same Oct. 18, 2016
-
Patent Title: Antibodies reactive with b7-h3 and uses thereof Sep. 13, 2016
-
Patent Title: Deimmunized serum-binding domains and their use in extending serum half-life Jun. 28, 2016
-
Patent Title: Covalent diabodies and uses thereof Mar. 29, 2016
-
Patent Title: Covalent diabodies and uses thereof Mar. 15, 2016
-
Patent Title: Her2/neu-specific antibodies and methods of using the same Jan. 26, 2016
-
Patent Title: Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof Oct. 06, 2015
-
Patent Title: Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use Aug. 04, 2015
-
Patent Title: Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity Jun. 16, 2015
-
Patent Title: Identification and engineering of antibodies with variant fc regions and methods of using same May. 12, 2015
-
Patent Title: Bcr-complex-specific antibodies and methods of using same Mar. 31, 2015
-
Patent Title: Fcγriib specific antibodies and methods of use thereof Mar. 03, 2015
-
Patent Title: Identification and engineering of antibodies with variant fc regions and methods of using same Feb. 10, 2015
-
Patent Title: Fcγriib specific antibodies and methods of use thereof Feb. 03, 2015
-
Patent Title: Her2/neu-specific antibodies and methods of using same Aug. 12, 2014
-
Patent Title: Antibodies reactive with b7-h3 and uses thereof Aug. 12, 2014
-
Patent Title: Compositions for the prevention and treatment of smallpox Aug. 05, 2014
-
Patent Title: Fcγriib—specific antibodies and methods of use thereof Jul. 22, 2014
-
Patent Title: Fcγriib specific antibodies and methods of use thereof Jul. 22, 2014
-
Patent Title: Combination of fcγriib-specific antibodies and cd20-specific antibodies and methods of use thereof Jul. 15, 2014
-
Patent Title: Identification and engineering of antibodies with variant fc regions and methods of using same Apr. 15, 2014
-
Patent Title: Bcr-complex-specific antibodies and methods of using same Mar. 11, 2014
-
Patent Title: Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity Mar. 04, 2014
-
Patent Title: Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for fcγr Feb. 18, 2014
-
Patent Title: Fcγriib specific antibodies and methods of use thereof Sep. 10, 2013
-
Patent Title: Identification and engineering of antibodies with variant fc regions and methods of using same May. 21, 2013
-
Patent Title: Kid3 and kid3 antibodies that bind thereto May. 14, 2013
-
Patent Title: Identification and engineering of antibodies with variant fc regions and methods of using same Jul. 10, 2012
-
Patent Title: Humanized fcγriib-specific antibodies and methods of use thereof Jul. 10, 2012
-
Patent Title: Antibodies to oncostatin m receptor Jul. 10, 2012
-
Patent Title: Engineering fc antibody regions to confer effector function Jul. 10, 2012
-
Patent Title: Tes7 and antibodies that bind thereto Jul. 10, 2012
-
Patent Title: Fcγriib specific antibodies and methods of use thereof Jun. 05, 2012
-
Patent Title: Identification and engineering of antibodies with variant fc regions and methods of using same Jun. 05, 2012
-
Patent Title: Transferrin receptor antibodies May. 29, 2012
-
Patent Title: Fcγriib specific antibodies and methods of use thereof May. 29, 2012
Federal grants, loans, and purchases
Estimated quarterly amount awarded to MGNX from public contracts
Recent insights relating to MGNX
Recent picks made for MGNX stock on CNBC
ETFs with the largest estimated holdings in MGNX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $MGNX stock a Buy, Sell, or Hold?
- What is the price target for $MGNX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $MGNX stock?
- Who owns the most shares of $MGNX stock?
- What funds own $MGNX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MGNX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
- Address Rockville, MD
- Market Cap 88.6 million
- Employees 341
- Industrial Classification Pharmaceutical Preparations